March 27, 2013
RiNA GmbH and NeoVentures Biotechnology Inc. jointly announce that they have agreed to enter into a strategic alliance to provide their clients with as full an aptamer discovery, development and commercial production service as possible. This agreement will enable NeoVentures clients to have access to RiNA delivery of spiegelmer based diagnostics, and enable RiNA clients to have access to NeoVentures proprietary positions in the areas of Dubbles selection, sequence analysis, and proprietary diagnostic platforms as well as experience in the commercial delivery of aptamer based diagnostics. Both companies remain committed to displacing antibodies with aptamers as the method of choice for diagnostic platforms. For more information please contact the companies directly at firstname.lastname@example.org or email@example.com.
January 31, 2013
NeoVentures Biotechnology Inc. is pleased to announce that they have retained the services of Dr. Michael Blind for the co-marketing of their custom aptamer development services in Europe. Dr. Blind brings his experience with aptamer technology and business planning from his leadership of NascaCell, a pioneering company in this area. Both Dr. Blind and NeoVentures are committed to promoting the use of aptamers where they make business sense for clients
November 30, 2012
NeoVentures has entered into a collaborative working relationship with AptaIT to provide our customers with an option for a premium service based on next generation sequencing of selected libraries. Next generation sequencing offers tremendous potential The in terms of identifying all potential binding sequences in a selected library as well as to determine shifts in selected motifs over rounds of selection. Declining costs for accessing this platform in combination with the global leadership that AptaIT have demonstrated with their development of motif identification software for large databases provides us with an opportunity to provide an added service to our clients. We are committed to leading innovation in aptamer identification and development for the benefit of our clients.
November 27, 2012
NeoVentures Biotechnology Inc. is pleased to announce that they have entered into a supply agreement with Cosmo Bio Co, Ltd. http://www.cosmobio.co.jp/index_e.asp for distribution of NeoVentures products and services in Japan. Cosmo
Bio is a leading life science distributor in Japan, with a commitment to building sustainable relationships with their clients. This agreement will position Cosmo Bio as the leading supplier of aptamer based goods and services in Japan.
November 22, 2012
NeoVentures announces the introduction of the NeoRating on published aptamers within their aptamer catalogue. We have noted that many aptamers that have been published simply do not work very well. The potential use of aptamers that do not bind well to their targets is not helpful for the development of the aptamer industry. As a service to our customers we assigned our chemistry team to review published DNA aptamers within our database and to provide a ranking based on the clear demonstration of published binding assays. The Neo Rating (Like/Dislike) should be considered as our opinion only. We welcome feedback from anyone who has used these aptamers and has data to suggest that our opinion is wrong. We also realize that we have missed published aptamers. If you have a published aptamer that you would like us to rate and post on the database please send us the information. We are interested in the sequence, and a clear demonstration of binding affinity to free target. We will synthesize aptamers that we have rated as Dislike, but we want clients to be aware of what they are purchasing.
October 24, 2012
NeoVentures will be providing Aptamer Workshops in selected cities globally. The first workshop will be held at the MaRS Discovery Centre, 101 College Street, Toronto, Canada on January 22nd, 2013. For more information and to register for this event, please click on Aptamer Workshop Brochure. Please watch this website for more information regarding a possible workshop in your area. If you think we should consider your area, please contact us to let us know. We are taking the show on the road… We look forward to meeting many of you whom we have worked with in person for the first time.
August 14, 2012
NeoVentures Biotechnology has developed the TouCH Platform, a novel approach for crop improvement. NeoVentures is developing this platform in a separate division of the company called Cropomics. Information regarding the development of the TouCH Platform will be supported on a separate website www.cropomics.com in order to maintain clarity for outside partners. The parliamentary secretary for agriculture, Pierre Lemieux, announced yesterday the awarding of a grant for the development of this technology to NeoVentures at their research facility in London, Ontario, Canada [News Release ].
July 10, 2012
Dr. Gregory Penner of NeoVentures Biotechnology Inc. has recently published an article on their experience commercializing diagnostic based on aptamers in IVD Technology Magazine; Commercialization of an aptamer-based diagnostic test.. The article provides an overview of the strengths and weaknesses of aptamers as an alternative to antibody based platforms.
July 4, 2012
Due to increasing requests NeoVentures is now providing a do-it-yourself
support service for custom aptamer identification. For a basic fee of $5,000
Cdn. we will help guide you through your own custom aptamer identification
process in your own laboratory. The service includes design of an appropriate
RNA or DNA selection strategy for your target molecule, a starting library of
oligonucleotides, guidance throughout the selection process, sequence analysis
to help you determine which sequences to test for binding assays, as well as
design and interpretation of binding assays, ultimately leading up to
identification of a useful aptamer. We are still providing our popular full
custom aptamer identification service using our expertise and our own
equipment. We do not provide a guarantee on the outcome of the Do-It-Yourself
program like we do with our custom identification service.
For more information on selecting your own aptamer please visit our
Custom Aptamer page in this website.
May 22, 2012
NeoVentures is pleased to announce the commerical release of Ultra-Fast Cleanup Column for HPLC analysis of aflatoxin M1 in milk. This new product provides the same ultra-fast clean up characteristics as the existing Ultra-Fast Cleanup Column product line. Total column processing time is reduced to a few minutes due to lower volumes required for loading, washing and elution. Elutions can be directly injected into your HPLC system without a need for dry down. Whole milk can be analyzed in the cleanup columns without a need for a defatting step. Fore more information, please see our product page.
NeoVentures Biotechnology Inc. is an aptamer company. We produce and sell aptamer based diagnostic products. This supports our core business of complete aptamer diagnostic product support. We are the clear global leader for companies looking for a partner to assist them with all aspects of aptamer based product development including, identification, product development, and commercial production.
We are committed to promoting the effective application of aptamers where they make compelling business sense. This means providing clear and full information regarding the strengths and weaknesses of aptamers both technically and commercially. We provide this information through our video series, and through our workshops. To join our mailing list, and be informed of new videos, or a workshop in your area, please contact us at, firstname.lastname@example.org.
NeoVentures is a privately owned, Canadian company. Our products and services are available in Japan through CosmoBio.
- Apta IT
- RiNA GmbH
- Foss (Denmark)
- Canada Bread
- The Hospital for Sick Children (Toronto)
Industrial Research Assistance Program